Background: Three years of treatment with either sublingual or subcutaneous allergen immunotherapy has been shown to be effective and to induce long-term tolerance. The Gauging Response in Allergic Rhinitis to Sublingual and Subcutaneous Immunotherapy (GRASS) trial demonstrated that 2 years of treatment through either route was effective in suppressing the response to nasal allergen challenge, although it was insufficient for inhibition 1 year after discontinuation. Objective: We sought to examine in the GRASS trial the time course of immunologic changes during 2 years of sublingual and subcutaneous immunotherapy and for 1 year after treatment discontinuation.
Methods: We performed multimodal immunomonitoring to assess allergen-specific CD4 T-cell properties in parallel with analysis of local mucosal cytokine responses induced by nasal allergen exposure and humoral immune responses that included IgE-dependent basophil activation and measurement of serum inhibitory activity for allergen-IgE binding to B cells (IgEfacilitated allergen binding). Results: All 3 of these distinct arms of the immune response displayed significant and coordinate alterations during 2 years of allergen desensitization, followed by reversal at 3 years, reflecting a lack of a durable immunologic effect. Although frequencies of antigen-specific T H 2 cells in peripheral blood determined by using HLA class II tetramer analysis most closely paralleled clinical outcomes, IgE antibody-dependent functional assays remained inhibited in part 1 year after discontinuation. Conclusion: Two years of allergen immunotherapy were effective but insufficient for long-term tolerance. Allergenspecific T H 2 cells most closely paralleled the transient clinical outcome, and it is likely that recurrence of the T-cell drivers of allergic immunity abrogated the potential for durable tolerance. On the other hand, the persistence of IgE blocking antibody 1 year after discontinuation might be an early indicator of a protolerogenic mechanism. (J Allergy Clin Immunol 2018;141:1750-60.)
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Allergen immunotherapy is an effective treatment option for patients with allergic rhinitis who do not respond adequately to the usual antihistamine and topical corticosteroid medications. 1 Subcutaneous immunotherapy involves weekly administration of incremental doses of allergenic material by means of injection, followed by monthly maintenance injections for several years. [2] [3] [4] Immunotherapy has been associated with overall changes in Tcell function with cytokine changes that suggest a shift from T H 2 cells toward T H 1 phenotypes or induction of regulatory T cells. 5, 6 These alterations are accompanied by decreases in recruitment, activation, or both of allergic effector cells, including mast cells, eosinophils, and basophils, in target organs. 7, 8 Measurement of serum immunoglobulins directed against the allergen in such immunotherapy studies indicates that specific IgG, particularly of the IgG 4 subclass, can be induced by therapy and is presumed to be mechanistically linked to clinical benefit by virtue of competitive inhibition of allergic responses triggered by specific IgE directed to the same allergens. [9] [10] [11] [12] [13] [14] [15] and epicutaneous 16, 17 routes. For food allergens, the oral route has also shown promising results. 18, 19 Because immunologic properties at each of these sites differ, the mechanisms through which these forms of allergen immunotherapy exert their therapeutic effects can differ as well.
The Gauging Response in Allergic Rhinitis to Sublingual and Subcutaneous Immunotherapy (GRASS) clinical trial was a randomized, placebo-controlled, double-blind study of 106 adults with a clinical history of moderate-to-severe seasonal allergic rhinitis caused by grass pollen. Study participants received 2 years of subcutaneous immunotherapy, sublingual immunotherapy, or placebo and were extensively studied over 3 years for clinical and immunologic parameters of response. 20 Clinical assessments in this trial were reported recently, demonstrating successful suppression of the nasal response to allergen challenge after 2 years of therapy through both the subcutaneous and sublingual routes, with lack of sustained benefit in the subsequent untreated third year. 20 We now report immunologic findings from this trial, including peripheral blood cellular and humoral assessments, as well as local tissue responses to allergen: evaluation of antigen-specific CD4 1 T cells in peripheral blood, functional outcomes from changes in the humoral response detected in serum and peripheral IgE-dependent basophil assays, and cytokine responses to allergen challenge in the nasal mucosa.
METHODS

Sample collection
Clinical characteristics of the subjects in the GRASS trial and details of the protocol have been reported previously. 20 Subcutaneous alum-adsorbed grass pollen immunotherapy (Alutard SQ Grass Pollen; ALK-Abell o, Hørsholm, Denmark) or matched placebo subcutaneous injections were given weekly for 15 weeks, followed by monthly maintenance injections until 2 years. Freeze-dried grass pollen (Phleum pratense) sublingual tablets (Grazax; ALK-Abell o) or matched placebo sublingual tablets were self-administered daily for 2 years. Timothy grass-specific IgE and specific IgG 4 levels were quantified by using the CAP FEIA system (Phadia, Uppsala, Sweden). Peripheral blood lymphocytes were collected and prepared for cryopreservation, as previously described. 20 Coded samples were provided to the operator.
Tetramer assays and flow cytometric analysis
Timothy grass-specific CD4 1 T-cell epitopes were identified by using tetramer-guided epitope mapping. 21, 22 Epitope-specific pMHC tetramer reagents were generated by loading specific peptides onto biotinylated soluble DR monomers and subsequently conjugated with phycoerythrin (PE)-streptavidin. 23 These included HLA-DR04:01, HLA-DR03:01, HLA-DR04:01, HLA-DR07:01, HLA-DR10:01, and HLA-DR11:01 tetramer reagents. For ex vivo tetramer staining, 20 to 40 million frozen PBMCs from subjects with HLA genotypes corresponding to these tetramers were thawed and resuspended in 200 mL of T-cell culture medium and, to enhance tetramer staining, were treated with dasatinib (Sigma-Aldrich, St Louis, Mo) for 10 minutes at 378C before tetramer staining. 24 PE-labeled pooled tetramers were then added to a final concentration of 20 mg/mL, and staining was carried out for 100 minutes at room temperature. A 1/100 fraction of the cells was saved, and the rest of the PE tetramer-positive cells were then enriched by using the anti-PE bead enrichment protocol through a magnetic column, according to the manufacturer's protocol (Miltenyi Biotec, Bergisch Gladbach, Germany). 22, 25 Cells in both the enriched fraction and the precolumn fraction were stained with a panel of antibodies of interest, including CD14 (HCD14; BioLegend, San Diego, Calif), CD19 (HIB19; BioLegend), CD45RA (HI100; BD Biosciences, San Jose, Calif), CD4 (RPA-T4; BD Biosciences), chemoattractant receptor-homologous molecule expressed on T H 2 lymphocytes (CRTH2; BM16; BD Biosciences), CD161 (PK136; BioLegend), and CD27 (O323; BioLegend) and were treated further with BD Via-Probes (BD Biosciences) before flow cytometry. Frequencies of tetramer-positive cells were calculated by using the formula n/N, where n is the number of tetramer-positive cells in the enriched fraction, and N is the total number of cells in the sample, which can be calculated by counting the number of cells in the precolumn fraction and multiplying by 100. The efficiency of recovery was optimized by using less than 30 million cells as starting material on samples with less than 300 tetramer-positive cells per million, capturing greater than 95% of the PE tetramer-stained populations.
Isolation of grass pollen allergen-reactive T cells with the CD154 upregulation assay
Global grass pollen-reactive CD4
1 T cells were tracked by using the CD154 assay. 26, 27 Briefly, frozen/thawed PBMCs were cultured at a density of 10 6 /mL with 1 mL/mL Timothy grass pollen crude extract and 1 mg/mL anti-CD40 blocking mAb (HB14; Miltenyi Biotec). After 18 hours of stimulation at 378C, cells were harvested and labeled with PE-conjugated anti-CD154 mAb for 10 minutes at 48C. Cells were then washed, labeled with anti-PE magnetic beads, and enriched by using a magnetic column, according to the manufacturer's instructions (Miltenyi Biotec). Magnetically enriched cells were next stained with antibodies against markers of interest and analyzed on a FACSAria II flow cytometer (BD Biosciences). Live memory CD45RO
1 CD154 1 CD4 1 T cells were sort purified for subsequent transcript analysis.
Real-time PCR expression analysis
The Fluidigm BioMark 96.96 Dynamic Array (Fluidigm, South San Francisco, Calif) 28 was used to measure gene expression in small cell populations. Ten cells per well were sorted by using FACS in quadruplicate in 96-well plates containing a reaction mix for reverse transcription (CellsDirect One-
Step qRT-PCR kit; Invitrogen, Carlsbad, Calif) and preamplification with 96 selected gene primer pairs (DELTAgene assays; Fluidigm). After sorting, samples were reverse transcribed and preamplified for 18 cycles. Primers and dNTPs were removed by means of incubation with Exonuclease I (New England Biolabs, Ipswich, Mass), and samples were diluted (53) with TE buffer and stored at 2208C. Samples and assays (primer pairs) were prepared for loading onto 96.96 Fluidigm Dynamic arrays, according to the manufacturer's recommendations. The 96.96 Fluidigm Dynamic Arrays were primed and loaded on an IFC Controller HX (Fluidigm), and real-time PCR was run on a BiomarkHD (Fluidigm). Data were collected and analyzed by using Fluidigm Real-Time PCR Analysis software (version 4.1.2).
Measurement of nasal cytokines
Nasal challenge was performed with Aquagen (ALK-Abell o) Phleum Pratense (Timothy grass) extract, as described previously. 20 The challenge dose was determined according to a dose-titration challenge at screening. The same dose was then used at the baseline (pretreatment) nasal challenge visit and at each subsequent challenge visit. The dose range was 1500 BU/mL (equivalent to 1.0 mg/mL major allergen) to 30,000 BU/mL (equivalent to 20.2 mg/mL major allergen).
Nasal secretions were collected by using synthetic polyurethane sponges precut to 20 3 15 3 15 mm (RG 27 grau; Gummi-Welz GmbH, Neu-Ulm, Germany) and sterilized by means of autoclaving. A single sponge was inserted into each of the participant's nostrils posterior to the mucocutaneous junction by a study physician under direct vision by using croc forceps and a nasal speculum (Phoenix Surgical Instruments, Hertfordshire, United Kingdom). Sponges were left in place for 2 minutes before removal and then added to 2-mL centrifuge tubes with indwelling 0.22-mm cellulose acetate filters (Costar Spin-X; Corning, Corning, NY). Tubes were kept briefly on ice before being centrifuged. At baseline, sponges were centrifuged ''neat'' without adding an elution buffer. At years 2 and 3, 75 mL of elution buffer After thawing, nasal fluid was analyzed for cytokines in yearly batches. Measurements of IL-4, IL-5, IL-10, IL-13, and IFN-g levels were performed with the MSD Human TH1/TH2 7-Plex, Ultra-Sensitive Kit, according to the manufacturer's instructions (MS6000 7 spot; Meso Scale Discovery, Rockville, Md). Briefly, after incubation of plates with diluent, 25 mL of samples, calibrators, and high and low standards were added to appropriate wells and incubated on a plate shaker for 2 hours. Plates were then washed in PBS plus 0.05% Tween-20 by using an automated washer (AquaMax 2000). Twentyfive microliters of detection antibody at 1 mg/mL was added to wells, followed by incubation on a plate shaker for 2 hours in the dark. Plates were then washed 3 times as before. One hundred and fifty microliters of Read Buffer T was then added to each well before plates were read on an Meso Scale Discovery SECTOR 6000 instrument. All measurements were performed in duplicate and reported as mean values per standardized volume. The assay was validated for analysis of nasal secretion, and the level of quantification was 5 to 5000 pg/mL for all cytokines.
IgE-facilitated allergen binding and basophil activation
Serum inhibitory activity for IgE-facilitated allergen binding (IgE-FAB) and presentation was measured by using the FAB assay. 10, 29, 30 Briefly, an indicator serum containing a high concentration of Timothy grass pollen (P pratense)-specific IgE (>100 IU/mL) was preincubated with 1 mg/mL allergen at 378C for 1 hour to allow formation of allergen-IgE complexes. Indicator serum and test serum (baseline year 1, year 2, and year 3) or RPMI alone as a control was mixed to test for inhibition of FAB. During this step, CD23-enriched EBV-transformed B cells were washed 3 times by means of centrifugation in RPMI 1640 at 423g for 7 minutes at 48C. Cells were then resuspended in FAB buffer (138.60 mmol/L NaCL, 1.12 mmol/L NaH 2 ) were added to the IgE serum/allergen complexes and incubated for 1 hour at 48C on ice. Cells were then washed twice to remove any unbound allergen-IgE complexes and immunostained with PE-labeled anti-human IgE (Miltenyi Biotech) for 45 minutes at 48C on ice. Cells were then washed and resuspended in FAB buffer, the percentage of cells bound by allergen-IgE complexes was assessed by using flow cytometry (BD FACSCanto II; BD Biosciences), and data were analyzed with FACSDiva software (BD Biosciences). Five thousand gated cells were analyzed, and all samples were measured in triplicate.
Assessment of ex vivo allergen-induced basophil responsiveness by using flow cytometry was performed on heparinized whole blood. Briefly, whole blood was incubated with or without 100 ng/mL P pratense extract (ALK-Abell o) in a 378C water bath for 15 minutes. Cells were immunostained with anti-human CD3, CD303, CD294 (CRTH2), and CD63 (all from BD Biosciences). Erythrocytes from whole blood were lysed with BD Lysing Solution (BD Biosciences) for 10 minutes at room temperature in the dark, samples were centrifuged (for 5 minutes at 200g), and supernatants were discarded. The resulting cell pellets were washed in 3 mL of PBS (without Ca 21 and Mg 21 ) and resuspended in 450 mL of ice-cold fixative solution (CellFix; BD Biosciences) before acquisition on the BD FACSCanto II flow cytometer (BD Biosciences). Activated cells were also identified as CD63 1 CRTH2 1 basophils. Analyses were performed with FlowJo software (version 10.2; FlowJo, Ashland, Ore).
Statistics
In the GRASS trial the intention-to-treat population included 106 randomized participants, 92 of whom provided an evaluable primary end point at 3 years. 20 The per-protocol (PP) population included 84 participants who remained in the study for 3 years, were compliant with study medications (defined as taking > _50% of their study medication for the duration of the study), and had an evaluable primary end point. All mechanistic data were assessed in the PP population by using a linear mixed model adjusted for baseline values. To be consistent, clinical end points, nasal challenge-induced Total Nasal Symptom Score area under the curve, and peak nasal inspiratory flow change from prechallenge area under the curve were reanalyzed in the PP population by using a linear mixed model adjusted for baseline values.
The threshold for significance was a P value of less than .05 (2-sided). Because all analyses were considered exploratory, P values were not adjusted for multiple comparisons. Analyses were performed with SAS software (version 9.4; SAS Institute, Cary, NC) and R software (version 3.2.4; R Foundation for Statistical Computing).
Data and materials availability
Data sets and figures from this study, along with clinical data from the GRASS trial, are available on TrialShare, the Immune Tolerance Network data visualization portal, which is available at https://www.itntrialshare.org/ GRASSmech.url.
Study approval
Written informed consent was received from participants before inclusion in the study. The study was approved by the National Research Ethics Committee in the United Kingdom. 
RESULTS
Peripheral antigen-specific T cells
Allergen-specific T-cell responses were assessed by means of direct ex vivo HLA class II tetramer staining of CD4 1 lymphocytes from peripheral blood. Peptide epitopes from the major timothy grass pollen allergens Phl p 1 and Phl p 5, which were used for tetramer production, are shown in Table I ; HLA genotypes in Table I were matched for each subject analyzed. Fig 1  shows representative flow cytometric analysis of these allergenspecific T cells from a study participant receiving subcutaneous grass allergen immunotherapy. Detection of lymphocytes that bind tetramers, consisting of timothy grass peptides bound to HLA class II molecules, identifies CD4 T cells specific for the grass pollen allergen. As shown in Fig 1, A, 
/CD161
1 cells and increased frequencies of CD27 1 cells. This altered pattern of cell-surface markers indicates a phenotypic change consistent with a loss of T H 2 cells in the circulating allergen-specific compartment. However, after 1 additional year off therapy, this phenotypic profile has reverted back to the original distribution of allergic markers, once again displaying increased frequencies of CRTH2 1 and CD161 1 cells and reduced frequencies of CD27 1 cells in the allergenspecific CD4 T-cell compartment. Fig 1, B , summarizes these profiles for 53 of 84 of the PP population (subcutaneous immunotherapy, 16; sublingual immunotherapy, 21; placebo, 16) enrolled in the GRASS clinical trial for whom there was adequate HLA matching for tetramer profiling of allergen-specific T cells. In placebotreated participants allergen-specific CD4 T-cell frequencies were stable over 3 years. Participants in both the subcutaneous and the sublingual therapy arms of the trial showed significant decreases compared with placebo-treated subjects in frequencies of allergen-specific cells during the first year of treatment, a time point at which clinical parameters in the 2 arms were also similar (Fig 1, C) . This downward trend continued in the group receiving a second year of subcutaneous therapy and remained significant compared with placebo-treated subjects, whereas the decrease appeared to plateau in the sublingual group compared with the placebo group at year 2 (Fig 1, B) . The decrease in overall CD4 antigen-specific cells (Fig 1, B, left panel) reflects the specific decrease in numbers of T H 2 cells (Fig 1, B, right panel) . After 2 years of therapy, subjects receiving subcutaneous therapy had fewer allergenspecific T H 2 cells in peripheral blood compared with the sublingual therapy group. Notably, 1 year after discontinuation of allergen therapy, specific CD4 T-cell numbers in both treatment groups returned to baseline frequencies, indicating a lack of a durable immunologic effect.
These antigen-specific T-cell profiles are remarkably concordant with the clinical parameters measured in the GRASS trial. 20 This is shown in Fig 1, C, for symptom-related outcomes of the PP subjects studied in the trial, with clinical outcomes measured on the same day as collection of samples used for T-cell analysis: the Total Nasal Symptom Score, a composite clinical index (scale 0-12) of the severity of nasal symptoms after nasal allergen challenge, and peak nasal inspiratory flow, an objective measurement of nasal airflow obstruction, for the same subjects and time points. Clinical improvement was seen with both forms of immunotherapy over the 2-year period of treatment but reverted back to baseline allergic parameters at year 3, which was 1 year after discontinuation of treatment. Thus the allergen-specific CD4 1 T-cell frequencies measured by using flow cytometry of tetramer-binding cells closely paralleled clinical outcomes.
Effects of therapy on local T H 2 cytokines
Nasal allergen challenges were performed before treatment and at yearly intervals with collection and cytokine analysis of nasal fluids. Nasal allergen challenge-induced increases in IL-4, IL-5, and IL-13 levels in nasal fluids were suppressed significantly after 2 years of treatment with either subcutaneous or sublingual immunotherapy, as shown in Fig 2. There was no treatment effect on IFN-g or IL-10 responses, indicating that both treatment modalities selectively reduced local T H 2 cytokines. Similar to what we observed with allergen-specific T H 2 cells in peripheral blood and in parallel with clinical outcomes in Fig 1, C , suppression of these local T H 2 cytokine responses to nasal allergen provocation was not maintained 1 year after therapy cessation at year 3.
These changes in mucosal cytokine levels together with fewer circulating allergen-specific T H 2 cells suggest an overall decrease in T H 2 immunity in desensitized subjects. We confirmed this interpretation through transcriptional analysis of antigen-reactive memory CD4
1 T cells at baseline and year 2 (see Fig E1, A, in this article's Online Repository at www.jacionline.org). 27, 31 For these experiments, cryopreserved PBMCs were stimulated with Timothy grass extract overnight in the presence of anti-CD40, and upregulation of CD154 on memory CD4
1 T cells was used to identify allergen-reactive T cells. Similar to the tetramer assay, both subcutaneous and sublingual treatment modalities reduced the frequency of allergen-reactive memory CD4 1 T cells in peripheral blood at year 2, but this reduction was only statistically significant for subcutaneous immunotherapy. These CD154 1 cells were isolated by using fluorescence-activated cell sorting, and RNA was extracted for transcriptional analysis, as shown in Fig E1, B. The CD27 2 population of allergen-reactive cells displayed a characteristic T H 2 transcript profile with increased IL-4, IL-5, IL-13, IL-31, and ST2 expression, which is consistent with a T H 2-predominant phenotype of allergen-specific CD4 1 T cells affected by specific immunotherapy.
Humoral immunologic outcomes
As previously reported, Timothy grass pollen-specific IgG 4 levels increased during allergen immunotherapy in parallel with the therapeutic response. 9, 10 To assess the functional capacity of this induced IgG, we measured the ability of postimmunotherapy serum to inhibit the binding of allergen-IgE complexes to B cells (IgE-FAB), an in vitro surrogate of IgE-facilitated antigen presentation. In this assay serum from patients who have received allergen-specific immunotherapy was evaluated for its ability to inhibit this allergen-IgE complex binding. 10 As shown in Fig 3,  A, there was a marked decrease in IgE-FAB during allergen immunotherapy for both subcutaneously and sublingually treated J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 5 FIG 1. Analysis of allergen-specific CD4 T cells and the relationship to clinical parameters measured during the GRASS trial. A, Representative flow cytometric analysis of tetramer-bound allergen-specific T cells from a study subject receiving allergen subcutaneous immunotherapy (SCIT). Lymphocytes that bind the pooled tetramers are displayed on the y-axis, and expression of the phenotypic cell-surface markers CD4, CRTH2, subjects. Interestingly, after 2 years of therapy, changes in allergen-specific IgG 4 /IgE ratios were 10-fold greater after subcutaneous compared with sublingual immunotherapy (Fig 3, B) , whereas changes in IgG-associated inhibitory activity for IgE-FAB were comparable for the 2 groups. At the 3-year follow up, 1 year off therapy, IgE-FAB binding trended back to baseline values but remained significantly decreased relative to that in placebo-treated participants. This pattern was similar to the profile reflected in the allergen-specific IgG 4 /IgE ratio (Fig 3, B) .
Basophil activation is another indicator of the IgE-mediated allergic response, which can be monitored ex vivo by means of detection of basophil surface activation markers after incubation of grass pollen allergen with whole blood. 32, 33 Similar to what was observed for serum inhibitory activity for IgE, both therapies significantly suppressed grass pollen allergen-induced basophil hyperresponsiveness, as measured by surface CD63 expression. This effect persisted at the year 3 follow-up, which was 1 year after withdrawal of treatment (Fig 3, C) .
Relationships between local tissue and systemic immunologic parameters
The overall concordance between decreased nasal T H 2 cytokine measurements, lower peripheral blood antigen-specific CD4 1 T-cell counts, and antigen-specific IgE activity after 2 years of allergen desensitization therapy suggested coordinated immune mechanisms. To explore the relationship between treatment effects on these immunologic parameters, each was plotted for individual subjects as year 2 fold change from baseline in a 3-dimensional scatter plot. Indeed, we identified a distinct coclustering of study participants within the immunotherapy treatment arms, which were well demarcated from the placebo-treated control subjects (Fig 4) . Many participants cluster near the origin of the graph, indicating synchronous allergen-specific CD4 1 T-cell, nasal T H 2 cytokine, and antibody changes, suggesting that the changes observed reflect the same shift in the immune responses, even though differences in significance compared with placebo are observed. There was no difference between the subcutaneous and sublingual treatment groups, which cluster together in this analysis at the end of 2 years of desensitization therapy.
DISCUSSION
Allergic manifestations are largely driven by T H 2-mediated immune mechanisms, and allergen-specific immunotherapy can inhibit, deviate, and/or delete these effector responses. In the GRASS clinical trial immunologic assays were used to directly compare different immune modalities, monitoring subjects by using a highly sensitive and specific tetramer assay to identify and phenotype allergen-specific CD4
1 T cells, a sensitive and quantitative measurement of in vivo allergen-provoked nasal cytokines used to measure local mucosal immunity and 2 assessments of peripheral allergen-specific IgE reactivity, namely inhibitory activity for IgE-FAB and inhibition of allergen-stimulated peripheral basophil activation. The distinctive opportunity to conduct this study in the context of a randomized placebo-controlled trial comparing 2 different forms of allergen administration in human subjects is unique, as is the integration of immunobiology for antigen-specific peripheral blood T cells and humoral immunity with in vivo target organ immune response after allergen exposure.
The 3 modalities tested, specific T cells, local cytokines, and specific humoral immunity, were generally concordant during treatment, as demonstrated by movement toward the origin of both subcutaneously and sublingually treated populations in Fig  4. Thus despite the fundamentally different routes of allergen administration and treatment between sublingual and subcutaneous therapy, with corresponding site-specific differences in antigen presentation, allergen immunotherapy through either route of exposure similarly reduced the immunologic effectors of the allergic response in each case. However, differences were evident in the magnitude, timing, and duration of effect: allergen-specific CD4
1 T-cell numbers were decreased in frequency after 1 year of treatment through either the subcutaneous or sublingual route and continued to decrease during therapy for a second year only in subjects receiving subcutaneous allergen immunotherapy. This decrease occurred within the T H 2 subpopulation of allergenspecific memory T cells characterized by expression of CRTH2 and CD161 and lack of expression of CD27. 22 Transcript analysis of allergen-reactive CD4 1 T cells, purified by using the parameter of CD154 upregulation after allergen exposure in vitro, confirmed loss of the T H 2 phenotype (see Fig E1) . Similar kinetics were found in the serum immunoglobulin compartment: therapeutic increases in the specific IgG 4 /IgE ratio, as well as decreases in facilitated IgE-binding assay results, were seen with both forms of specific immunotherapy but were more prominent earlier (1 year after initiation of therapy) in the subcutaneous treatment arm.
Clinical symptoms improved in the GRASS trial participants during therapy, but this response was not durable. When assessed 1 year after discontinuation of treatment, subjects receiving either form of immunotherapy regained their responses to allergen challenge, indicating a lack of immune tolerance. 20 Of the 3 types of immunologic characteristics studied, circulating T cells, local tissue cytokines, and systemic immunoglobulins, the allergenspecific CD4
1 T-cell frequencies and nasal T H 2 cytokine levels showed a close temporal relationship with clinical outcome, reverting back to baseline values after cessation of therapy at year 3. This supports the concept that future clinical studies for allergen tolerance might need to focus on more durable strategies for deleting or deviating the allergen-specific T-cell compartment; an example is the current CATNIP (Anti-TSLP Plus AntigenSpecific Immunotherapy For Induction Of Tolerance In CD27, CD161, and CCR4 are displayed on the x-axis at baseline, at 2 years after continuous SCIT therapy, and at 3 years (after 1 year off therapy). B, Frequencies of allergen-specific CD4 T cells were determined for 53 HLA-DR4 subjects in the GRASS trial by means of tetramer binding (left panel). Frequencies of T H 2 cells are identified by
Total Nasal Symptom Score (TNSS) average area under the curve (AUC); (left panel) and peak nasal inspiratory flow (PNIF) average AUC (right panel) for 0 to 10 hours after allergen challenge were measured at baseline and years 1 to 3 for all participants treated with sublingual immunotherapy (green), subcutaneous immunotherapy (red), and placebo (blue). Significant differences are indicated as follows: *P < .05 and **P < .01. Data are shown as means with 95% CIs for the 84 PP subjects enrolled in the GRASS trial.
= J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 5 Individuals With Cat Allergy) clinical trial (NCT 02237196) combining anti-thymic stromal lymphopoietin with allergenspecific immunotherapy. IgG 4 /IgE measurement and functional assays of IgE-FAB and basophil activation showed a slightly different pattern compared with the T-cell responses (Fig 3) . Increases in specific IgG 4 /IgE ratios and inhibition of IgE-FAB (which is known to be largely IgG 4 associated 34 ) were less marked for sublingual compared with subcutaneous immunotherapy at year 1. In contrast to the T-cell response, changes in IgG 4 /IgE blocking activity in the intervention groups persisted until year 3, which was 1 year after discontinuation, although the magnitude was reduced compared with the year 2 values. This could reflect simply a slower change in immunoglobulin levels compared with T-cell profiles over time or might indicate the potential for uncoupling of B cell-associated responses, raising the possibility that B cells might be more amenable to the long-term tolerance effects of specific immunotherapy. Cytokine levels in nasal fluid after nasal allergen challenge. Levels of the cytokines IL-4, IL-5, and IL-13 in nasal fluid for 10 hours after nasal allergen challenge are displayed from study subjects at baseline, after 2 years of desensitization, and at 3 years, which was 1 year after discontinuation of desensitization therapy. Participants treated with sublingual immunotherapy (SLIT) are displayed in green, participants treated with subcutaneous immunotherapy (SCIT) are displayed in red, and participants treated with placebo are displayed in blue. Data are shown as means with 95% CIs.
FIG 3.
Allergen-specific IgE-dependent functional assays. A, Effect of the IgG 4 increase on the ability of allergen-IgE complexes to bind B cells was measured by using the IgE-FAB assay. Sera from patients were evaluated for the ability to inhibit allergen-IgE complex binding at baseline and years 1 to 3. B, Grass pollen-specific IgG 4 and IgE levels were monitored, and the IgG 4 /IgE ratio is displayed for subjects at baseline, after years 1 and 2 during desensitization therapy, and at 3 years, which was after discontinuation of therapy. C, Basophil surface activation markers from whole blood of participants treated with sublingual immunotherapy (SLIT; green), subcutaneous immunotherapy (SCIT; red), and placebo (blue) at baseline and years 1 to 3 after incubation with grass pollen allergen. Significant differences are indicated as follows: *P < .05 and **P < .01. Data are shown as means with 95% CIs.
Previous studies of allergen-responsive T cells during immunotherapy have revealed immune deviation away from T H 2 responses in favor of T H 1 responses, 35, 36 whereas others have shown no change in T-cell phenotype. 37, 38 PBMCs harvested during immunotherapy have shown suppression of allergenstimulated proliferation accompanied by increases in levels of TGF-b, 39 ,40 IL-10, 39,41-43 or both in culture supernatants or by using an ELIspot assay. 44 These changes were accompanied by increases in numbers of phenotypic regulatory T cells, as determined by means of flow cytometry. 36, [39] [40] [41] In 2 studies immunotherapy-induced suppression of allergen-stimulated Tcell proliferation was reversed by addition of either anti-IL-10 36 or TGF-b soluble receptor 40 to the cultures. Suppression of allergen-reactive T H 2 cells by measurement of allergenstimulated CD154
1
CD4
1 T cells has been shown previously during subcutaneous immunotherapy, 45 whereas studies of class II tetramer-positive T cells have been variable, with trials suggesting either decreases 22, 46, 47 or no change 48 in tetramer-positive cells after immunotherapy. The present study demonstrates clear decreases in tetramer-positive phenotypic T H 2 cells that parallel the clinical response during and after specific immunotherapy, which is similar for both subcutaneous and sublingual modes of allergen administration.
Transient increases in specific IgE levels and IgG 4 /IgE ratios have been demonstrated previously 9, 10 but not in a long-term comparison of sublingual and subcutaneous immunotherapy. 20 In this study, although onset of blocking antibody activity was slower for sublingual immunotherapy, it persisted at 3 years of follow-up and was equivalent to that observed for subcutaneous immunotherapy despite a 10-fold lower increase in the specific IgG 4 /IgE ratio for sublingual immunotherapy after 2 years of desensitization (Fig 3) . This highlights likely differences between the 2 routes of delivery, where local antigen processing through the sublingual route might result in fewer IgG 4 antibodies but higher avidity and/or affinity and greater IgE-blocking activity. The transient clinical benefit from 2 years of immunotherapy in the GRASS trial stands in contrast to previous allergy clinical trials 49, 50 that demonstrated more durable benefit from 3 years of treatment, suggesting that 3 years of desensitization might be required for sustained effects. Our finding of a close temporal relationship between the frequency of allergen-specific circulating T H 2 cells and this transient clinical outcome could represent a causal relationship in that recurrence of the T-cell ''drivers'' of allergic immunity might have abrogated the potential for durable tolerance. On the other hand, persistence of IgE-blocking antibody 9, 20 might be an early indicator of a protolerogenic mechanism. If this hypothesis is correct, then future strategies for allergen immunotherapy could be directed at both enhancing persistent depletion of the allergen-specific T H 2 cell population for optimal induction of tolerance and augmenting the antigen-specific therapeutic B-cell response for maintenance of long-term effect. levels are displayed in color scale from high (yellow) to low (blue). Genes are grouped by category, with T H 2-related genes in red, apoptosis-related genes in gray, and T H 1-related genes in purple.
